• Elobixibat Hydrate: Precision IBAT Inhibition for GI & Metab

  2026-04-21

  Elobixibat hydrate, a selective ileal bile acid transporter inhibitor, transforms chronic idiopathic constipation and metabolic research through targeted bile acid modulation. This guide delivers actionable experimental workflows, troubleshooting strategies, and context-rich protocol parameters, all anchored by robust clinical data and APExBIO’s quality assurance.

• MG-132 Proteasome Inhibitor: Advanced Workflows in Cancer Re

  2026-04-21

  MG-132 (Z-LLL-al) stands at the forefront of proteasome inhibitor research, enabling precise control of apoptosis, autophagy, and cell cycle arrest. This guide translates recent breakthroughs and essential troubleshooting into actionable protocols, maximizing the utility of MG-132 in oxidative stress and cancer model systems.

• Verbascoside as a PKC/NF-κB Inhibitor in Osteoclastogenesis

  2026-04-20

  Verbascoside stands out as a precision PKC/NF-κB inhibitor, enabling high-specificity modulation of inflammatory and bone metabolic pathways in vitro. This article translates the latest research and hands-on protocols into actionable workflows—empowering cell signaling and osteoclastogenesis studies with robust troubleshooting and comparative insight.

• Low-Molecular Weight Inhibitors Targeting the Alternative Co

  2026-04-20

  Schubart et al. (2023) review advances in the development of orally available, low-molecular weight inhibitors targeting key proteases in the alternative complement pathway, primarily complement factor B and D. Their analysis highlights both the mechanistic underpinnings and translational potential of these inhibitors for treating diseases driven by complement dysregulation, such as paroxysmal nocturnal hemoglobinuria and C3 glomerulopathy.

• Revisiting Sumatriptan Metabolism: CYP and MAO Pathways Unve

  2026-04-19

  This study challenges conventional assumptions about sumatriptan metabolism by demonstrating that, beyond monoamine oxidase A (MAO A)-mediated deamination, cytochrome P450 (CYP) enzymes also contribute to N-demethylation. These findings refine our understanding of drug metabolism relevant to neuropharmacology and may impact future design of neuroactive compounds.

• Applied Workflows for Pomalidomide (CC-4047) in Hematologica

  2026-04-18

  Pomalidomide (CC-4047) empowers advanced hematological malignancy research with robust immunomodulation and precise assay control. This guide covers hands-on workflows, protocol optimization, and troubleshooting strategies to maximize reproducibility and impact in multiple myeloma and erythroid progenitor cell studies.

• InstaBlue Protein Stain Solution: Precision Protein Visualiz

  2026-04-17

  Explore how InstaBlue Protein Stain Solution accelerates protein visualization for RNA-targeted therapy research. This article uniquely connects fast, sensitive gel staining to the evolving demands of gene silencing and protein quantification in modern biomedical innovation.

• Firefly Luciferase mRNA: Enhanced 5-moUTP Workflows & Assays

  2026-04-16

  EZ Cap™ Firefly Luciferase mRNA (5-moUTP) sets a new standard for low-immunogenicity, high-stability reporter assays and mRNA delivery studies. Unlock data-driven, reproducible workflows with advanced capping, poly(A) tail engineering, and 5-moUTP modification—ideal for robust translation and sensitive in vivo imaging.

• Thermal Shift Assays Reveal Ligands for Bacterial Sensors

  2026-04-15

  This review details recent advances in the use of thermal shift assays for identifying ligands that bind bacterial sensor proteins. It highlights methodological refinements, discusses reliability challenges, and outlines the impact of ligand discovery on understanding bacterial signaling and environmental adaptation.

• AT13387: Optimizing Hsp90 Inhibition in Cancer Biology Resea

  2026-04-14

  AT13387 is a next-generation Hsp90 inhibitor with distinct chemical structure and exceptional potency for disrupting oncogenic signaling in cancer models. This article delivers hands-on protocol guidance, advanced troubleshooting, and actionable insights for leveraging AT13387 in apoptosis induction and cell cycle arrest studies, translating cutting-edge research into robust experimental workflows.

• A-1210477: Precision MCL-1 Inhibitor for Cancer Apoptosis As

  2026-04-13

  A-1210477 empowers researchers to dissect MCL-1-dependent apoptosis with high selectivity and potency, enabling robust mitochondrial pathway assays in cancer cells. This article delivers actionable workflows, protocol optimizations, and troubleshooting tips to maximize experimental success with this next-generation MCL-1 inhibitor.

• Mechanistic Innovation: Advancing Genome Editing with EZ Cap

  2026-04-12

  This thought-leadership article delivers a mechanistic and strategic perspective for translational researchers on leveraging EZ Cap™ Cas9 mRNA (m1Ψ) with Cap1 structure and N1-Methylpseudo-UTP modification for next-generation CRISPR genome editing. Integrating peer-reviewed insights on mRNA nuclear export regulation, immune evasion, and editing specificity, the article elevates the discussion beyond protocols and troubleshooting to provide advanced guidance for designing high-fidelity, reproducible editing workflows in mammalian cells.

• NU6300 Blocks Gasdermin D Cleavage: New Insights into Pyropt

  2026-04-12

  Jiang et al. reveal that NU6300 covalently modifies cysteine-191 of gasdermin D, blocking its cleavage and palmitoylation and thus inhibiting pyroptotic cell death. This mechanism offers a promising strategy for targeting inflammasome-driven diseases, with implications for translational research in inflammation and cell death pathways.

• Talabostat Mesylate (PT-100): Applied Workflows in Tumor Mic

  2026-04-11

  Talabostat mesylate (PT-100) offers targeted modulation of the tumor microenvironment through dual inhibition of DPP4 and FAP. This guide translates recent research into actionable protocols, emphasizing workflow optimization, troubleshooting, and advanced applications for cancer and immunology labs.

• Cefodizime: Third-Generation Cephalosporin for Robust Antimi

  2026-04-11

  Cefodizime empowers microbiology researchers with reliable, broad-spectrum antibacterial activity and immunomodulatory benefits, making it ideal for respiratory and urinary tract infection models. This article delivers actionable workflow guidance, protocol optimization, and troubleshooting tips, grounded in both bench research and real-world resistance monitoring.

454 records 21/31 page Previous Next First page 上5页 2122232425 下5页 Last page